Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO

被引：0

作者：

Rexer, H. ^{[1
]}

Retz, M. ^{[2
]}

Albers, P. ^{[3
]}

机构：

[1] MeckEvidence, AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany

[2] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany

[3] Univ Klinikum Dusseldorf, Urol Klin, Dusseldorf, Germany

来源：

UROLOGE | 2016年 / 55卷 / 11期

关键词：

D O I：

10.1007/s00120-016-0248-5

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1491 / 1493

页数：3

共 50 条

[41] Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study [J].

Rentsch, Cyrill A. ;

Hayoz, Stefanie ;

Cathomas, Richard L. .

EUROPEAN UROLOGY, 2022, 81 (05) :542-542

[42] First-line Treatment for advanced Renal Cell Carcinoma A Phase 3, open-label, randomized Study of Atezolizumab (Anti-PD-L1-Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with untreated advanced Renal Cell Carcinoma ("IMmotion") AN 37/15 of AUO [J].

Rexer, H. ;

Doehn, C. .

UROLOGE, 2016, 55 (09) :1242-1243

[43] A phase 3, randomized, open-label, multicenter, global study of Durvalumab and bacillus calmette-Guerin (BCG) vs BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC) [J].

Boegemann, M. ;

Abdrashitov, R. ;

Casuscelli, J. ;

Feyerabend, S. ;

Hatiboglu, G. ;

Hegele, A. ;

Hellmis, E. ;

Klier, J. ;

von Klot, C. ;

Schmitz-Draeger, B. ;

Spiegelhalder, P. ;

Stagge, E. ;

De Santis, M. .

ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 :105-105

[44] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). [J].

De Santis, Maria ;

Abdrashitov, Ramil ;

Hegele, Axel ;

Kolb, Margaret ;

Parker, Suzanne ;

Redorta, Juan Palou ;

Nishiyama, Hiroyuki ;

Xiao, Feng ;

Gupta, Ashok Kumar ;

Shore, Neal D. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

[45] A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection [J].

Yan, S. ;

Zhang, Y. ;

Bi, X. ;

Zhao, J. ;

Du, S. ;

Huang, Z. ;

Zhang, Y. ;

Liu, D. ;

Li, Z. ;

Zhou, J. ;

Cai, J. ;

Zhao, H. .

ANNALS OF ONCOLOGY, 2019, 30

[46] A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). [J].

Gao, Jianjun ;

Siefker-Radtke, Arlene O. ;

Navai, Neema ;

Campbell, Matthew T. ;

Tidwell, Rebecca Slack ;

Guo, Charles ;

Kamat, Ashish M. ;

Matin, Surena F. ;

Araujo, John C. ;

Shah, Amishi Yogesh ;

Msaouel, Pavlos ;

Blando, Jorge M. ;

Vence, Luis M. ;

Duan, Fei ;

Basu, Sreyashi ;

Singh, Shalini ;

Zhao, Hao ;

Allison, James Patrick ;

Dinney, Colin P. N. ;

Sharma, Padmanee .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[47] Neoadjuvant Therapy Schemes combined with adjuvant Therapy for Patients with muscle invasive Bladder Cancer before or after radical Cystectomy A randomized, open, multicenter, global Phase-III Study to Determine the Efficacy and Safety of Durvalumab in combination with Gemcitabine plus Cisplatin (G plus C) for neoadjuvant Treatment, followed by Durvalumab alone for adjuvant Treatment in Patients with muscle invasive Bladder Cancer ( NIAGARA) - AUO AB 74/20 [J].

Rexer, Heidrun ;

Kuebler, Hubert ;

Retz, Margitta .

AKTUELLE UROLOGIE, 2021, 52 (03) :220-221

[48] Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013 [J].

Martinez-Pineiro, Luis ;

Portillo, Jose A. ;

Fernandez, Jesus M. ;

Zabala, Jose A. ;

Cadierno, Iker ;

Moyano, Jose L. ;

Solsona, Eduardo ;

Unda, Miguel ;

Beardo, Pastora ;

Rodriguez-Molina, Jesus ;

Chantada, Venancio ;

Palou, Joan ;

Muntanola, Pedro ;

Alonso Dorrego, Jose M. ;

Perez-Garcia, Franciso J. ;

Silva, Juan M. ;

Chesa, Nicolas ;

Montesinos, Manuel ;

Ojea, Antonio ;

Madero, Rosario ;

Martinez-Pineiro, Jose A. .

EUROPEAN UROLOGY, 2015, 68 (02) :256-262

[49] Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score (vol 83, pg 432, 2024) [J].

Galsky, Matthew D. ;

Bajorin, Dean F. ;

Witjes, Johannes Alfred ;

Gschwend, Juergen E. ;

Tomita, Yoshihiko ;

Nasroulah, Federico ;

Li, Jun ;

Collette, Sandra ;

Valderrama, Begona P. ;

Grimm, Marc-Oliver ;

Appleman, Leonard ;

Gravis, Gwenaelle ;

Necchi, Andrea ;

Ye, Dingwei ;

Stenner, Frank ;

Wind-Rotolo, Megan ;

Zhang, Joshua ;

uensal-Kacmaz, Keziban .

EUROPEAN UROLOGY, 2024, 85 (03) :e96-e97

[50] A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). [J].

Rischin, Danny ;

Fury, Matthew G. ;

Lowy, Israel ;

Stankevich, Elizabeth ;

Han, Hyunsil ;

Porceddu, Sandro .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →